Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Spinal Cord Injury - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 20 Dec 17

The "Spinal Cord Injury - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Spinal Cord Injury - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 8, 1, 29 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Spinal Cord Injury - Overview
  4. Spinal Cord Injury - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Spinal Cord Injury - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Spinal Cord Injury - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Acorda Therapeutics Inc
  • Aevi Genomic Medicine Inc
  • Apollo Endosurgery Inc
  • Asterias Biotherapeutics Inc
  • Athersys Inc
  • BioArctic AB
  • BioAxone BioSciences Inc
  • Biogen Inc
  • CSL Ltd
  • CSPC Pharmaceutical Group Limited
  • Genervon Biopharmaceuticals LLC
  • Hemostemix Inc
  • Histocell SL
  • K-Stemcell Co Ltd
  • Kadimastem Ltd
  • Kringle Pharma Inc
  • MandalMed Inc
  • Mapreg SAS
  • Neuralstem Inc
  • Neuronax SAS
  • New World Laboratories Inc
  • Pharmicell Co Ltd
  • PixarBio Corp
  • RDD Pharma Ltd
  • RespireRx Pharmaceuticals Inc
  • SanBio Inc
  • Spectrum Pharmaceuticals Inc
  • Stemedica Cell Technologies Inc
  • TissueGene Inc
  • Tumorend LLC
  • Vertex Pharmaceuticals Inc
  • Vicore Pharma AB

For more information about this report visit

View source version on

Business Wire

Last updated on: 20/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.